Latest news with #AndrewHider
Yahoo
4 days ago
- Business
- Yahoo
Insider Stock Buying Reaches CA$2.74m On ATS
Multiple insiders secured a larger position in ATS Corporation (TSE:ATS) shares over the last 12 months. This is reassuring as this suggests that insiders have increased optimism about the company's prospects. Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Notably, that recent purchase by Andrew Hider is the biggest insider purchase of ATS shares that we've seen in the last year. So it's clear an insider wanted to buy, even at a higher price than the current share price (being CA$40.36). It's very possible they regret the purchase, but it's more likely they are bullish about the company. In our view, the price an insider pays for shares is very important. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels. Over the last year, we can see that insiders have bought 65.70k shares worth CA$2.7m. On the other hand they divested 5.33k shares, for CA$220k. In the last twelve months there was more buying than selling by ATS insiders. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below! Check out our latest analysis for ATS There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying. Over the last three months, we've seen significantly more insider buying, than insider selling, at ATS. In fact, 10 insiders bought CA$2.6m worth of shares. But we did see insider selling worth CA$220k. Insiders have spent more buying shares than they have selling, so on balance we think they are are probably optimistic. Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. ATS insiders own about CA$32m worth of shares. That equates to 0.8% of the company. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders. It is good to see recent purchasing. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Insiders likely see value in ATS shares, given these transactions (along with notable insider ownership of the company). While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. At Simply Wall St, we found 1 warning sign for ATS that deserve your attention before buying any shares. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Reuters
07-07-2025
- Business
- Reuters
Baxter International taps Andrew Hider as CEO
July 7 (Reuters) - Baxter International (BAX.N), opens new tab on Monday named Andrew Hider as the medical device maker's new top boss, succeeding longtime CEO Jose Almeida. Hider previously served as CEO of ATS Corporation ( opens new tab, a company that designs and builds machinery for industries including medical devices, food and beverage, and pharmaceuticals. During his eight-year tenure at ATS, Hider oversaw multiple product launches and led acquisitions of companies such as Avidity Science, Heidolph, and Transformix Engineering, strengthening ATS's life sciences portfolio. He also spent 10 years at Danaher (DHR.N), opens new tab, a life sciences and diagnostics company, holding various leadership positions. "Andrew's leadership at global, diversified companies underscores his ability to manage complex operations and generate value for shareholders," said Baxter interim CEO Brent Shafer, who will transition to independent chair of the board. Baxter has experienced robust demand for its intravenous (IV) solutions after a supply disruption last year caused by hurricane-related flooding at one of its manufacturing facilities. The company said that Hider will assume his new role no later than September 3, taking over from Almeida, who stepped down in February. Almeida's retirement followed Baxter's $3.8 billion spinoff of its kidney care unit. During his tenure, Baxter acquired hospital bed-maker Hill-Rom for $10.5 billion and shifted its focus away from the biopharma business. Under Almeida's leadership, the company's shares more than doubled to $90 in the initial years, only to shed gains during the post-pandemic years.
Yahoo
07-07-2025
- Business
- Yahoo
Medical Equipment Maker Baxter International Names New CEO
Baxter International on Monday named Andrew Hider, chief executive of Canadian automation solutions firm ATS Corp., its new CEO. Deerfield, Illinois-based Baxter (BAX), a medical equipment company with a market capitalization of roughly $15 billion, said Hider would "assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments." Brent Shafer, who has served as interim CEO at Baxter since February, will remain board chair once Hider assumes his role. Cambridge, Ontario-based ATS (ATS) said Hider, its CEO since 2017, would be stepping down "to pursue a new leadership opportunity outside the automation industry." It added that Hider's departure "is expected to be by the end of August on a date to be determined by the Board," and that CFO Ryan McLeod would serve as interim CEO upon his exit. Shares of both companies fell on Monday afternoon, with those of Baxter declining by more than 4% and those of ATS dropping by about 8.3%. Baxter stock remains slightly positive for the year but ATS shares moved into negative territory for 2025 on the news. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-07-2025
- Business
- Yahoo
Baxter International appoints new CEO, months after former leader abruptly retired
Deerfield-based Baxter International has named a new president and CEO, about five months after its former leader abruptly retired. Andrew Hider will serve as the new CEO of Baxter no later than Sept. 3, the company announced Monday morning. Hider, 48, is now CEO of ATS Corporation, which provides automation solutions for companies in the life sciences, food and beverage, transportation, consumer products and energy industries. Baxter makes IV fluids, a number of pharmaceuticals and other hospital products. Hider will earn an annual base salary of $1.35 million, with the potential to earn an annual bonus equal to 150% of his salary, as well as being eligible to participate in the company's long term incentive equity program. He will also receive a one-time sign-on payment of $1 million, as well as various other payments and benefits. Baxter's current chair and interim CEO Brent Shafer, called Hider an 'exceptional leader with a strong track record of operational excellence, disciplined execution and innovation,' in a news release. Hider said in the release that he looks forward to working with the board and his new colleagues to 'redefine healthcare delivery while driving sustainable, long-term growth.' 'Baxter has undergone a significant transformation over the last few years, refocusing the company and better positioning it for the future,' Hider said. In February of this year, Baxter announced that then-CEO and Board Chair José Almeida would retire, effective immediately. Baxter did not say at the time why Almeida was retiring effective immediately, but Almeida said in a news release, 'With the key elements of our broad strategic transformation complete, this is the right time for a new CEO to lead the company into its next chapter.' Almeida had led the company since 2016, and his retirement was announced just days after Baxter closed on its sale of its kidney care business to global investment firm Carlyle for $3.7 billion. That business is now a new company called Vantive with headquarters in Deerfield. Baxter's sale of its kidney care business was part of a three-pronged strategy, intended to strengthen and transform the company after facing significant challenges. In late 2021, Baxter acquired medical equipment and technology company Hillrom for $10.5 billion. The following year, Baxter revealed an impairment charge of $3.1 billion related to the acquisition, meaning Hillrom was no longer worth what Baxter had paid for it. As part of its restructuring following the acquisition, Baxter said in 2023 that it planned to lay off less than 5% of its workers across the globe. Baxter also focused last year on ramping back up production of IV solutions, after its largest manufacturing plant, in North Carolina, was damaged by Hurricane Helene – a situation that alarmed hospitals that depend on those fluids. That plant is now back up to its pre-hurricane production levels. As the new CEO, Hider may also have to deal with fallout from potential tariffs. Baxter's chief financial officer said during a May earnings call that tariffs could cost the company $60 million to $70 million this year, though he said a majority of the products Baxter sells in the U.S. are manufactured in the U.S. and consist largely of U.S.-made components. Sign in to access your portfolio
Wall Street Journal
07-07-2025
- Business
- Wall Street Journal
Baxter International Names ATS' Hider as Next Chief Executive Officer
Baxter International BAX -0.95%decrease; red down pointing triangle has appointed Andrew Hider as president, chief executive officer and a board member. The medical products maker said Hider will assume his responsibilities no later than Sept. 3 or an earlier date pending completion of his current employment commitments. Hider has served as CEO of Canadian automation and technology company ATS since 2017.
